Back to search results
NCT05645536

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Enrolling by Invitation
PHASE3Ages 18–51InterventionalTreatment
Tolmar Inc.
~250 participants
Updated 2026-09-01 on ClinicalTrials.gov
What's tested:TOL2506TamoxifenLetrozole tabletsAnastrozole TabletsExemestane Tablets

At a glance

Recruiting sites
0 of 47 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Measured over 4 years from enrolling in study

Conditions

Breast Cancer

Explore related trials

Breast CarcinomaHR LYSINE DEMETHYLASE AND NUCLEAR RECEPTOR COREPRESSOR

NCT05645536

Where you'd take part

This study runs at 47 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Amiisto Atencion Medica Integral, Investigacion Y Terapia Oncologica S. A. DE C. V.

    Madero, Mexicono site contact published

  • Atencion Medica Integral E Investigacion en Terapia Oncologica

    Mexico City, Mexicono site contact published

  • Baptist Health Lexington

    Lexington, Kentuckyno site contact published

  • Baptist Health Louisville

    Louisville, Kentuckyno site contact published

  • Cape Fear Valley Health Systems - Cancer Center

    Fayetteville, North Carolinano site contact published

  • Centro de Estudos e Pesquisa de Hematologia e Oncologia

    Santo André, Brazilno site contact published

  • Centro Privado de MRI de Rio Cuarto SA

    Córdoba, Argentinano site contact published

  • Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazilno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Females:

What this trial measures

  • The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)4 years from enrolling in study